JCC: Analysis of cases of inflammatory enteropathy with new coronary pneumonia in Spain

BACKGROUND: Data are currently lacking on patients with inflammatory bowel disease (IBD) with the new coronavirus (SARS-CoV-2) disease (COVID-19) around the end of 2019Therefore, the purpose of this study is to report on the clinical characteristics of patients with COVID-19 in patients with IBD, including gastrointestinal symptoms, and to assess the risk of COVID-19 in patients with IBDmethod: The patients in this study were from laboratory-confirmed IBD patients with COVID-19The cumulative age-adjusted incidence rate was compared with the total population of the Madrid regionResults: As of April 8, 2020, 12 out of 1919 IBD patients were diagnosed with COVID-19The average age was 52, 75% of the patients were female, and 58.3% had Crohn's diseaseSeven patients (58 per cent) received maintenance therapy for immunomodulators/biologics, of which 4 received combination therapy (33 per cent)Eight patients (66%) required hospitalization (1 in intensive care unit, 2 deaths) and 4 patients were isolated at homeThe daily amount of diarrhea in nine patients was between 4 and 10 stools (average 5.4, standard deviation 1.6)Diarrhoea symptoms occurred in 5 patients (42%)In 2 patients, diarrhea is the only symptom that occursThe cumulative incidence of COVID-19 per 1000 PATIENTs was 6.1The adjusted incidence of COVID-19 in IBD patients was lower (OR 0.74, 95% CI 0.70-0.77; p.001), and the associated mortality rate was similar to that of the normal population (OR 0.95, 95% CI:0)84-1.06;conclusion: There was no increase in COVID-19 risk and associated mortality in IBD patients compared to the general populationIn many patients with IBD, diarrhea is a symptom, sometimes the only symptom of COVID-19 on set of episodes